CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for SYS6020, a BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy. This marks a significant milestone for the company as SYS6020 is positioned as the world’s first mRNA-LNP-based cell therapy to be approved for clinical trials.
SYS6020 is highlighted for its high cell viability and high CAR positivity rate, offering a promising therapy with no oncogenic risk due to genome integration. Additionally, it is designed to minimize side effects such as cytokine release syndrome (CRS), which is commonly associated with conventional CAR-T products. Preclinical studies have demonstrated that SYS6020 can significantly target and kill BCMA antigen-positive myeloma cells, exhibiting a favorable safety and efficacy profile.- Flcube.com
